<DOC>
	<DOCNO>NCT00305383</DOCNO>
	<brief_summary>The purpose study examine rapid virologic response ( RVR ) combination therapy ( CT ) Week 4 group receive standard combination peginterferon alfa-2b/viramidine dose regimen versus cohort receive 4 week viramidine monotherapy prior start peginterferon alfa-2b/viramidine combination therapy .</brief_summary>
	<brief_title>Viral Kinetic Study With Viramidine Therapy-Naive Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>This Phase 2b multicenter study , conduct solely United States , consist randomize , double-blind , monotherapy period , patient receive either viramidine placebo 4 week . After monotherapy period , patient receive viramidine plus peginterferon alfa-2b combination therapy 48 week open-label fashion participate 24-week follow-up period completion combination therapy . The RVR CT Week 4 group receive standard combination peginterferon alfa-2b/viramidine dose regimen versus cohort receive 4 week viramidine monotherapy prior start peginterferon alfa-2b/viramidine combination therapy examine . The difference virological response treatment end follow-up African-Americans Caucasians ( non-Hispanics ) , well correlation duration viral negativity ( DVN ) sustain virologic response ( SVR ) base race dose regimen , also assess .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Treatmentnaive , genotype 1 , compensate , chronic hepatitis C infect Caucasian AfricanAmerican patient Body weight great 61 kg 87.3 kg HCV RNA great 2 million copies/mL Elevated measure historical alanine aminotransferase Hemoglobin least 12.0 g/dL female least 13.0 g/dL male Calculated creatinine clearance great 70 mL/min Cirrhosis liver Alanine aminotransferase great 3 time upper limit normal Severe neuropsychiatric disorder History clinical manifestation significant metabolic , hematological , pulmonary , ischemic , unstable heart disease , gastrointestinal , neurological , renal , urological , endocrine , ophthalmologic disorder include severe retinopathy , immune mediate disease Other comorbid chronic viral infection include hepatitis B human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Viramidine</keyword>
	<keyword>Peginterferon alfa-2b</keyword>
	<keyword>Valeant</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Rapid virologic response</keyword>
	<keyword>HCV RNA</keyword>
</DOC>